Coherus BioSciences (NASDAQ: CHRS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “This morning, Coherus announced that toripalimab (tori) in combination with chemo significantly prolonged PFS and OS in patients with advanced esophageal squamous cell carcinoma (‘ESCC’), compared w/ chemo alone. Despite the press release not containing numbers, we had a look at the benchmark data for anti-PD1s in combo w/ chemo being studied in this indication, as well as its potential market size, to start to do work around it. Overall, an incremental win for Coherus as the Junshi thesis builds — which is still a debate among investors.”
To request access to the full report, visit https://ibn.fm/XlpAb
About Coherus BioSciences, Inc.
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system. In February 2021, Coherus and Junshi Biosciences announced a collaboration in which Coherus would in-license toripalimab, an anti-PD-1 antibody, in the United States and Canada. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business. Coherus markets UDENYCA(R) (pegfilgrastim-cbqv) in the United States and through 2023 expects to launch biosimilars of Humira(R), Avastin(R) and Lucentis(R), if approved. For more information, visit the company’s website at www.Coherus.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.